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The objective of this studywas to describe the occurrence of HIV dementia and
neuropsychological testing abnormalities in a new cohort of HIV-seropositive
individuals at high risk for HIV dementia and to compare these results to
a cohort before the advent of highly active antiretroviral therapy (HAART).
HAART has been associated with improvements in cognitive performance
in some HIV-infected patients. However, it is uncertain whether HAART has
changed the frequency of specic neurocognitive abnormalities. Baseline data
from 272 HIV-seropositive subjects in the Dana cohort recruited from January,
1994, to December, 1995, and 251 HIV-seropositive subjects in the Northeast-
ern AIDS Dementia Consortium (NEAD) cohort recruited from April, 1998, to
August, 1999, were compared. Participants in both cohorts received nearly
identical assessments. After adjusting for differences in age, education, gen-
der, race, and CD4 count between the two cohorts, there were no differences
in the occurrence of HIV dementia or abnormalities either 1 SD or 2 SDs be-
low established norms for any of the neuropsychological tests. Even though
HAART has reduced the incidence of HIV dementia, HIV-associated cognitive
impairment continues to be a major clinical problem among individuals with
advanced infection. Journal of NeuroVirology (2002) 8, 136–142.
Keywords: cognitive disorders; dementia; infections; neuropsychology;
behavior
Introduction
In the early 1990s, human immunodeciency virus
type 1 (HIV-1)-associated dementia complex (HIV de-
mentia) (Janssen et al, 1991) affected 16% of patients
with acquired immune deciency syndrome (AIDS)
and had an annual incidence of 7% among patients
with AIDS (McArthur et al, 1993). During this time
period, HIV dementia was frequently a complica-
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tion that progressed over several months to death
(Bouwman et al, 1998). The introduction of highly
active antiretroviral therapy (HAART) in 1996 has
resulted in suppression of systemic HIV-1 viral load
and improvements in survival for patients with HIV
infection (Brodt et al, 1997). HAART has also been
associated with an improvement in cognitive perfor-
mance (Sacktor et al, 2000a) and a decreased inci-
dence of HIV dementia (Brodt et al, 1997; Sacktor
et al, 1999), as well as improvement in neuroimaging
markers of HIV dementia (Chang et al, 1999; Sacktor
et al, 2000b). However, despite these advances, thera-
peutic failures with HAART still occur in about 50%
of patients (Fatkenheuer et al, 1997). It remains un-
certain whether the frequency of specic neurocog-
nitive abnormalities in HIV infection has changed.
In January 1994, the Charles A. Dana Foundation
established a consortium of three centers (Columbia
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University, Johns Hopkins University, and the Uni-
versity of Rochester) to recruit a cohort of individu-
als (Dana cohort) at high risk for the development of
HIV dementia to characterize their neurologic, cog-
nitive, psychiatric, and functional decits (The Dana
Consortium, 1996). At this time,monotherapy or dual
therapy were the predominant forms of treatment,
and a signicant number of individuals were still
naive to antiretroviral medications. In April, 1998,
a new National Institute of Neurological Disorders
and Stroke (NINDS)-funded consortium of three cen-
ters (Columbia University, Johns Hopkins University,
and the University of Rochester) known as the North-
eastern AIDS Dementia Consortium initiated a cohort
study (NEAD cohort) which was designed to investi-
gate the relationships between viral load, immune ac-
tivation, and progression of neurological dysfunction
in HIV infection. In November, 1999, a fourth cen-
ter at Northwestern University was added to the con-
sortium. In contrast to antiretroviral treatment in the
Dana cohort, HAART encompassing triple antiretro-
viral therapy was the predominant form of treatment
when the NEAD cohort was established. The cur-
rent study describes the characteristics of the NEAD
cohort, notes the occurrence of HIV dementia and
specic neuropsychological testing abnormalities at
baseline in the NEAD cohort, and compares the oc-
currence of HIV dementia and specic neuropsycho-
logical testing abnormalities at baseline in the two
longitudinal cohorts, one pre-HAART (Dana cohort)
and the other post-HAART (NEAD cohort), both re-
cruiting individuals with a high risk for HIV demen-
tia, using nearly identical assessment tools.
Results
Recruitment and composition of the cohort
Recruitment sources for each site were described
previously (The Dana Consortium, 1996). For the
272 subjects in the Dana cohort, 42.3% were from the
Johns Hopkins University site, 34.9% were from
the Columbia University site, and 22.8% were from
the University of Rochester site. Similarly, for the
251 subjects in the NEAD cohort, 45.0% were from
the Johns Hopkins University site, 31.9% were
from the Columbia University site, and 23.1% were
from the University of Rochester site.
Antiretroviral therapy
In the Dana cohort, 44% of subjects were on mono-
therapy, 11% of subjects were on dual therapy, and
43%of subjectswere on no therapy. In contrast, in the
NEAD cohort, 68% of subjects were on HAART, and
10% of subjects were on dual therapy (dened as two
antiretroviral drugs [without a protease inhibitor]).
In the Dana cohort, the most common antiretroviral
drugs used were zidovudine (45.2%) and didanosine
(15.1%). In contrast, in the NEAD cohort, the ma-
jority of subjects were on HAART regimes, includ-
Table 1 Demographic characteristics of Dana and NEAD cohorts
Dana NEAD
n = 272 n = 251
Recruitment years 1994–1995 1998–1999 P value
Age: years, mean (SD) 39.7 (7.5) 41.4 (7.3) 0.01
Male gender (%) 77.9 66.5 0.004
Ethnicity
(% White/Black/Hispanic) 50/40/7 21/66/12 <0.0001
Education: years, mean (SD) 13.5 (2.9) 12.3 (2.1) <0.0001
AIDS dening illness (%) 37.9 61.8 <0.001
CD4 C count, mean (SD) 177.9 (182.2) 129.1 (85.1) 0.71¤
¤ P value from t-test comparing log-transformed CD4 counts.
ing either stavudine (37.2%) or zidovudine (35.6%),
lamivudine (56.8%), and a protease inhibitor.
Demographic characteristics
The baseline demographic characteristics of the Dana
and NEAD cohorts are shown in Table 1. Subjects in
the NEAD cohort were slightly older (mean [SD] D
41.4 [7.3], P D 0:01) than subjects in the Dana cohort
(mean [SD] D 39.7 [7.5]). Compared to other cohorts
of HIV seropositive individuals, the Dana and NEAD
cohorts both include a high proportion of women
and subjects with minority ethnicity. As shown in
Table 1, a greater proportion of subjects in the NEAD
cohort were women (33% versus 22%, P D 0:004),
and African-American (66% versus 40%, P < 0:001),
and had fewer years of education (mean [SD] D 12.3
(2.1) versus 13.5 (2.9), P < 0:0001) compared to sub-
jects in the Dana cohort. Due to the inclusion criteria
there was no major difference in the CD4 lympho-
cyte count between the two cohorts, although sub-
jects in the NEAD cohort were more likely to have
had a previous AIDS-dening opportunistic infec-
tion (62% versus 38%, P < 0:001) than subjects in
the Dana cohort. It should be noted that the history
of an AIDS-dening illness variable was dened dif-
ferently for the NEAD and Dana cohorts, with more
AIDS dening illnesses in this variable in the NEAD
cohort than for the equivalent variable in the Dana
cohort.
Neurologic examination
The macroneurological exam score was lower in the
NEAD cohort (mean [SD] D 6.9 [5.2]) compared to
the Dana cohort (mean [SD] D 8.4 [5.6]) (P D 0:002),
suggesting less impairment in the neurological exam-
ination in the NEAD cohort. However, there was no
difference in the motor Unied Parkinson’s Disease
Rating Scale (UPDRS) score (NEAD—mean [SD] D 3.4
[4.9] versus Dana—mean [SD] D 4.8 [7.1]) (P D 0:21)
between the two cohorts. There was also no differ-
ence in the frequency of symptomatic distal sensory
polyneuropathy (NEAD—34.5% versus Dana—
34.7%) between the two cohorts. However, the fre-
quency of asymptomatic distal sensory polyneuropa-
thy was slightly greater in the NEAD cohort (29.3%)
compared to the Dana cohort (20.1%) (P D 0:03).
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Table 2 Dementia classication for subjects in the Dana and
NEAD cohorts
Dana NEAD
n = 272 n = 251 P value
AAN Classication (%)¤ 0.10
Normal 25.0 30.5
HIV-Minor cognitive/motor 47.7 37.4
disorder




Mild impairment 51.1 56.2
Moderate impairment 18.7 16.1
Severe impairment 4.5 3.7
¤Using a computerized algorithm as described previously (The
Dana Consortium, 1996).
Dementia and neuropsychological test assessments
As shown in Table 2, HIV-associated minor cog-
nitive/motor disorder, (HIV-MC/MD) was the most
common AAN classication for subjects in both the
Dana and NEAD cohorts (Janssen et al, 1991). There
were similar proportions of subjects rated as nonim-
paired and having HIV dementia in both cohorts. The
overall neuropsychologist’s impressionwas also sim-
ilar between the two cohorts.
The unadjusted mean (SD) score for each of the
neuropsychological tests is shown in Table 3. The
mean (SD) scores of subjects in theNEAD cohort were
worse in tests of verbal memory (Total score [P D
0:0001], Trial 5 score [P D 0:0002], Delayed recall
[P D 0:003], Recognition score [P D 0:002]), visual
memory (Rey Complex Figure Recall [P D 0:004]),
constructional skills (Rey Complex Figure Copy [P D
0:03]), and frontal systems (verbal uency [P D 0:03],
OddMan Out tests [P D 0:05]). However, after adjust-
ing for the differences in age, education, gender, race,
and CD4 count between the two cohorts, there were
no statistically signicant differences in the mean
score or in the frequency of abnormalities either 1 SD
or 2 SDs below the mean for any of the neuropsycho-
logical tests (see Table 3).
When analyses were restricted to subjects having
a CD4 count ·200 at baseline, the results were simi-
lar to those for the full cohorts. Additional analyses
were performed that compared the frequencies of HIV
dementia and neuropsychological testing abnormal-
ities among subjects in the Dana cohort, subjects in
the NEAD cohort taking HAART, and subjects in the
NEAD cohort not taking HAART. Again, after adjust-
ing for differences in age, education, gender, race, and
CD4 count among the three groups of subjects, there
were no statistically signicant differences among the
groups in the proportions of subjects who were rated
as not impaired or as having HIV dementia. The neu-
ropsychologist’s overall impression was also similar
among the three groups of subjects. Therewere no sig-
nicant differences among the groups in mean scores
or in the frequencies of abnormalities either 1 SD or
Table 3 Neuropsychological testing for subjects in the Dana and
NEAD cohorts
Dana NEAD
n D 272 n D 251 P value¤
Verbal and visual memory
RAVLT—Total, mean (SD) 44.6 (11.8) 41.0 (8.9) 0.33
2 SD below norm (%) 13.4 10.4 0.16
RAVLT—Trial 5, mean (SD) 11.0 (2.8) 10.1 (2.3) 0.15
2 SD below norm (%) 13.0 14.0 0.37
RAVLT—Delayed recall, 8.7 (3.6) 7.9 (3.0) 0.59
mean (SD)
2 SD below norm (%) 8.4 5.6 0.21
RAVLT—Recognition score, 13.0 (2.4) 12.3 (2.4) 0.30
mean (SD)
2 SD below norm (%) 14.1 14.0 0.99
RCF—Immediate recall, 16.6 (7.9) 14.7 (7.5) 0.40
mean (SD)
2 SD below norm (%) 7.6 10.5 0.06
Psychomotor and motor speed
GP-nondominant hand, 84.5 (22.6) 87.3 (22.7) 0.42
mean (SD)
2 SD below mean (%) 20.3 16.2 0.48
GP-dominant hand, 78.3 (23.5) 77.7 (18.2) 0.08
mean (SD)
2 SD below mean (%) 20.0 12.6 20.13
Symbol Digit, mean (SD) 47.1 (14.4) 45.6 (11.7) 0.19
2 SD below mean (%) 11.0 6.8 0.34
Constructional
RCF—copy, mean (SD) 30.1 (6.8) 28.8 (6.9) 0.70
2 SD below norm (%) 22.8 25.7 0.61
Frontal/Executive
Verbal uency (FAS), 38.8 (14.7) 36.2 (11.7) 0.32
mean (SD)
2 SD below norm (%) 3.4 3.6 0.20
Odd man out 36.3 (4.9) 35.4 (5.5) 0.94
2 SD below norm (%) 13.3 12.9 0.86
RAVLT—Rey Auditory Verbal Learning Test.
RCF—Rey Complex Figure.
GP—Grooved pegboard.
¤Adjusted for age, education, gender, race, and CD4 count.
2 SDs below the mean for any of the neuropsycholog-
ical tests.
Discussion
Despite the introduction of HAART in 1996, HIV-
associated cognitive impairment persists among HIV-
seropositive individuals with advanced infection.
HIV-associated cognitive impairment continues to be
characterized by prominent decits in psychomo-
tor/motor speed, verbal and visual memory, as well
as other cognitive domains.
One should not conclude that the incidence of HIV
dementia in the era of HAART is unchanged from
these results. The Dana and NEAD cohorts do not
represent all subjects with HIV infection. These co-
horts have purposefully recruited HIV-seropositive
individuals at high risk for HIV dementia and cog-
nitive impairment, by virtue of having a CD4 count
<200 or by demonstrating cognitive impairment with
a CD4 count <300. Thus, epidemiological results are
only relevant to this select group of patients, and
HIV-associated cognitive impairment after HAART
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not all individuals with HIV infection. However, as
of 1996, HIV-seropositive subjects with a CD4 count
<200 represented 53% of the US population with
HIV infection receiving medical care (Bozette et al,
1998).
There were several important demographic differ-
ences between subjects in the Dana cohort and sub-
jects in the NEAD cohort. The NEAD cohort had
a greater proportion of women, African-Americans,
and subjects with fewer years of education. These
demographic changes between HIV-seropositive
individuals in the early 1990s and HIV-seropositive
individuals in the late 1990s are representative of epi-
demiological changes in HIV infection in the United
States [Centers for Disease Control and Prevention
(CDC), 1996]. In 1996, according to the CDC, African-
Americans represented 41%of adults/adolescents re-
ported with AIDS, exceeding the proportion who are
Caucasian for the rst time (Centers for Disease Con-
trol and Prevention, 1996). Rates in women, those
who are injecting drug users, and those who contract
infection through heterosexual contact have contin-
ued to rise in the United States. Thus, the NEAD co-
hort, given its high representation of minorities and
women, will provide an excellent resource to evalu-
ate neurocognitive dysfunction among those individ-
uals most vulnerable for HIV-induced neurological
dysfunction in the coming decade.
In addition to differences in demographics, com-
pared to Dana cohort participants, subjects in the
NEAD cohort may represent individuals with more
advanced infection, as suggested by a greater propor-
tion of subjects with a previous AIDS-dening illness
(excluding CD4 count<200). Because HIV-associated
cognitive impairment is associated with more ad-
vanced immunodeciency, the lack of a difference
in the occurrence of cognitive impairment between
the Dana and NEAD cohorts could represent a ben-
ecial effect of HAART on a group of subjects (the
NEAD cohort) more likely to have cognitive impair-
ment because of more advanced infection. However,
another explanation is that the history of an AIDS-
dening illness variable was dened differently for
the NEAD and Dana cohorts, with more AIDS den-
ing illnesses in this variable in the NEAD cohort than
for the equivalent variable in the Dana cohort. This
may account for the increased frequency of an AIDS
dening illness among NEAD cohort subjects com-
pared to Dana cohort participants. Of note, there was
no major difference in the distribution of CD4 counts
between the two cohorts at the baseline visit for each
cohort. Data on the lifetime CD4 count nadir is not
available for subjects in the Dana and NEAD cohorts
to determine whether NEAD cohort subjects had a
history of greater immune dysfunction.
Another potential difference between the two co-
horts which could not be directly compared is the
effect of psychiatric comorbidity. Different assess-
ments of moodwere used for the two cohorts. The ex-
tent to which subthreshold major depression at base-
line may be contributing to cognitive impairment,
and whether the frequency and extent of psychiatric
comorbidity is different between the two cohorts is
unclear. Further studies examining the role of psy-
chiatric disease in subjects in the NEAD cohort are
underway.
A factor that could account for a lack of difference
in neuropsychological test results between the two
cohorts is poormedication adherence among subjects
in the NEAD cohort. If subjects in the NEAD cohort
were not adherent to their antiretroviral medications,
then they would be unlikely to have durable sup-
pression of plasma and cerebrospinal uid HIV RNA
levels, and thus may resemble subjects in the Dana
cohort on monotherapy and no therapy. Measures of
adherence are not available for either cohort. Another
potentially confounding factor is that some of the cog-
nitive abnormalities may relate to complications of
heavy drug/alcohol use rather than HIV itself. Equiv-
alent measures of drug use are not available for the
two cohorts.
An unsuppressed plasma or cerebrospinal uid
HIV RNA level was not part of the inclusion crite-
ria. High plasma HIV RNA levels prior to neuropsy-
chological testing have been associated with a greater
risk for developing HIV dementia (Childs et al, 1999),
and several reports demonstrate that elevated cere-
brospinal uid viral load correlates with neurocog-
nitive dysfunction (Ellis et al, 1997; McArthur et al,
1997). Patients with unsuppressed viral load with a
CD4 count >300 may also represent individuals at
high risk for cognitive impairment.
The NEAD consortium is a diverse cohort of sub-
jects with advanced infection that will provide a
unique opportunity to investigate the relationships
between plasma and cerebrospinal uid viral load,
markers of immune activation in the plasma, cere-
brospinal uid, and brain, and the progression of neu-
rologic dysfunction and functional impairment. Both
cross-sectional and longitudinal data from the NEAD




Participants in both theDana andNEAD cohorts were
recruited with identical inclusion and exclusion cri-
teria as described previously for the Dana consortium
(The Dana Consortium, 1996). Inclusion criteria for
the NEAD (and Dana) cohorts were HIV seropositive
based on self-report and conrmed by ELISA and
Western blot; capable of providing informed consent;
ambulatory at initial visit; and eithermeeting Centers
for Disease Control and Prevention criteria for AIDS
(CD4 count of <200) or with a CD4 count of <300
and demonstrating cognitive impairment (dened as
performance on neuropsychological testing that was
2 SDs below the appropriate mean on one test or 1 SD
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below themean on two tests). Exclusion criteria were
current or past opportunistic CNS infection at study
entry, with the exception of treated neurosyphilis;
history or current clinical evidence of schizophre-
nia or current severe affective disorder believed to
explain the subject’s cognitive impairment; and his-
tory of chronic neurologic disorders such as multiple
sclerosis or uncontrolled epilepsy. Current alcohol or
drug use was discouraged but was not grounds for ex-
clusion; however, subjects were not examined while
intoxicated.
Historical information and neurologic examination
Clinical data assessments for both the Dana and
NEAD cohorts were nearly identical. These proce-
dures have been described previously for the Dana
cohort (The Dana Consortium, 1996). For the NEAD
(and Dana) cohort, a structured questionnaire was
administered to each subject to obtain demographic
information and medical history, including HIV-1-
associated illnesses and medications. The neuro-
logical examination included the macroneurologic
examination created for the AIDS Clinical Trials
Group (ACTG) and the motor portion of the Unied
Parkinson’s Disease Rating Scale (UPDRS) (Fahn et al,
1987).
Neuropsychological examination
The neuropsychological examinations for both the
Dana and NEAD cohorts were identical. The neu-
ropsychological testing battery covered seven do-
mains. Verbal memory was assessed with the Rey
Auditory Verbal Learning Test (Rey, 1941). Impaired
performance on any of the components of the test
was evaluated (Total score, Trial 5 score, Delayed Re-
call, Recognition score, and Immediate Recall). Vi-
sual memory was assessed with the Rey Complex
Figure Recall test (Rey, 1941). Constructional skills
were assessed with the Rey Complex Figure Copy
(Rey, 1941). Psychomotor performancewasmeasured
with the Digit Symbol test (Wechsler, 1981). The Trail
Making test (Reitan, 1958; Reitan, 1979) was also ad-
ministered in theNEAD cohort, but these results were
not used in the clinical characterization of subjects so
that identical criteria could be used for both cohorts.
Motor speedwas assessedwith theGroovedPegboard
test (GP) with either the dominant or nondominant
hand (Klove, 1963). Frontal systems were assessed
with the Verbal Fluency (Benton, 1955) and the Odd
Man Out tests (Flowers and Robertson, 1985). Reac-
tion time was measured with the California Comput-
erized Assessment Package (CALCAP) (Miller et al,
1991). General intellectual performance was assessed
with the National Adult Reading Test (Nelson and
O’Connell, 1978; Nelson, 1982).
An age and education adjusted Z score was used
to quantify performance for each of the neuropsy-
chological tests. Scores for subjects with ·12 years
of education were compared with norms established
by the AIDS Link to Intravenous Experience (ALIVE)
study (Concha et al, 1995). In the ALIVE study the
mean (standard deviation [SD]) agewas 24 (6.9) years,
73.7% were men, 95% were African-Americans, and
the mean (SD) years of education for the entire study
was 11.6 (2.0) years. Scores for subjects with >12
years of education were compared with norms estab-
lished by theMulticenter AIDS Cohort Study (MACS)
(Selnes et al, 1991). In theMACS study, themean (SD)
age was 37 (7.6) years, 100% were men, 92% were
Caucasian, and the mean (SD) years of education for
the entire study were 16 (2.3) years.
Functional assessment
Functional assessments for both cohorts were iden-
tical. These measures included the Instrumental Ac-
tivities of Daily Living (IADL) scales of Lawton and
Brody (Lawton and Brody, 1969), the Katz Activ-
ities of Daily Living (ADL)/Lawton Personal Self-
Maintenance scale (Katz et al, 1963), the Role and
Physical Functioning items of the Medical Outcomes
Study (MOS) (Stewart and Ware, 1993), and the
Karnofsky Performance Scale (Karnofsky et al, 1948).
Psychiatric assessment
In the Dana cohort, the Center for Epidemiologic
Studies-Depression Scale (CES-D) was used to assess
mood (Radloff, 1977). In the NEAD cohort, the Beck
Depression Inventory was used (Beck et al, 1961).
Laboratory assessment
CD4 lymphocyte counts, hemoglobin, and hematocrit
levels were obtained in both cohorts. In the NEAD co-
hort, plasma and cerebrospinal uid viral load spec-
imens and immune activation markers were also col-
lected. The results from these assayswill bedescribed
in detail in future analyses. Viral load specimens
were not collected in the Dana cohort.
Dementia classication
The extensive neurologic, neuropsychological, func-
tional, and psychiatric assessments were used to
characterize subjects having HIV-associated minor
cognitive/motor disorder (MC/MD) or HIV demen-
tia (Janssen et al, 1991), according to the American
Academy of Neurology (AAN) criteria, as described
previously (The Dana Consortium, 1996). Other mea-
sures of cognitive performance included a Memo-
rial Sloan Kettering (MSK) dementia stage (Price and
Brew, 1988) assigned by a local consensus conference
including a neurologist and neuropsychologist at
each site, and an overall neuropsychologist’s impres-
sion, using only the neuropsychological test results.
Data analysis
Baseline data from 272 HIV-seropositive subjects in
the Dana cohort from January, 1994, to December,
1995, and 251 HIV-seropositive subjects in the NEAD
cohort from April, 1998, to August, 1999, were com-
pared. Subject recruitment at Northwestern Univer-
sity began after August, 1999, so these subjects were
not included as part of this analysis.
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Mean values for demographic, laboratory, neuro-
logic, and cognitive variables were compared be-
tween the Dana and NEAD cohorts using t tests. For
a small number of variables that did not appear to
be normally distributed (e.g., total macroneurologi-
cal exam score and motor UPDRS score), Wilcoxon
rank sum tests were used to compare the distribu-
tions among the groups. Chi-square tests were used
to compare proportions among the groups. The dis-
tributions of AAN dementia classications and over-
all neuropsychologist impressions were compared
among the groups after adjusting for group differ-
ences in age, education, gender, race, and CD4 count
using polytomous logistic regression. Proportions of
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